Presentation is loading. Please wait.

Presentation is loading. Please wait.

Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.

Published byStephen Francis Modified over 8 years ago

Similar presentations

Presentation on theme: "Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit."— Presentation transcript:

1 Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit

2 Long-Term Treatment of DVT/PE: 2 options VTE Toolkit LMWH S/C Oral Anticoagulation (INR 2.0 - 3.0) 5-7 d 3 mos.- indefinite 1

3 Long-Term Treatment of DVT/PE: 2 options VTE Toolkit LMWH S/C Oral Anticoagulation (INR 2.0 - 3.0) 5-7 d 3 mos.- indefinite 1 LMWH S/C ? 2 pregnancy, uncontrolled adenocarcinoma, high bleeding risk, patient preference

4 Treatment of VTE VTE Toolkit Recurrent VTE Anticoagulation Time 0 With anticoagulation, the risk of recurrent VTE is very low. VTE

5 Treatment of VTE VTE Toolkit Recurrent VTE Anticoagulation Time 0 If the VTE was provoked (surgery, trauma, pregnancy, acute illness, etc.), the risks of recurrent VTE after a period of anticoagulation is low. VTE

6 Treatment of VTE VTE Toolkit Recurrent VTE Anticoagulation Time 0 If the VTE was unprovoked, associated with cancer or some thrombophilias, the risks of recurrent VTE after a period of anticoagulation is higher. VTE

7 D-Dimer to Predict VTE Recurrence VTE Toolkit Patients with abnormal D-Dimer one month after discontinuation of anticoagulation have a significantly greater incidence of recurrent VTE than patients with a normal D-dimer. Palareti - D-Dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780

8 Predictors of Recurrent VTE VTE Toolkit Ongoing risk factors – cancer, immobility, high risk thrombophilia (APLA, AT deficiency) Unprovoked initial VTE Older age Male gender Obesity Residual DVT Elevated D-dimer 1 month after stopping anticoagulants

9 Duration of Treatment for VTE VTE Toolkit 1 st Episode: Transient, reversed risk3 - 6 mos. Unprovoked12 mos  indefinite* Ongoing risk (unresolved cancer, AT deficiency, APLA)indefinite* Recurrent Episodes:indefinite* * Periodic reassessment to discuss: 1)Patient risk factors for bleeding and thrombosis 2)New knowledge about risk of recurrence 3)Patient preference

10 Venous Disease Coalition www.vasculardisease.org/venousdiseasecoalition/ VTE Toolkit

Download ppt "Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit."

Similar presentations

Brian M. Johnson, MD CCRMC PBL 11/7/12

Brian M. Johnson, MD CCRMC PBL 11/7/12
ANTICOAGULATION WORKSHOP David Dale, MD MACP Eric Gamboa, MD FACP Iyad Hamarneh, MD September 13, 2014.

ANTICOAGULATION WORKSHOP David Dale, MD MACP Eric Gamboa, MD FACP Iyad Hamarneh, MD September 13, 2014.
Treatment of Acute Pulmonary Embolism

Treatment of Acute Pulmonary Embolism
Results: 1.Progression of thrombus length and volume (40% vs. 28%; P

Results: 1.Progression of thrombus length and volume (40% vs. 28%; P
Chapter Eleven Venous Disease Coalition Chronic Venous Insufficiency VTE Toolkit.

Chapter Eleven Venous Disease Coalition Chronic Venous Insufficiency VTE Toolkit.
Venous Thromboembolism in the Surgical Patient: Prophylaxis and Treatment Pamela Hebbard August 11, 2005.

Venous Thromboembolism in the Surgical Patient: Prophylaxis and Treatment Pamela Hebbard August 11, 2005.
 Incidence rate (symptomatic): 1%  ½ occur after discharge  We don’t understand which patients are at highest risk.

 Incidence rate (symptomatic): 1%  ½ occur after discharge  We don’t understand which patients are at highest risk.
Clinical Knowledge Summaries CKS Pulmonary embolism (PE)

Clinical Knowledge Summaries CKS Pulmonary embolism (PE)
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.

The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
Chapter Eight Venous Disease Coalition Safe Use of Oral Anticoagulants VTE Toolkit.

Chapter Eight Venous Disease Coalition Safe Use of Oral Anticoagulants VTE Toolkit.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.

Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.

CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Venous thromboembolism: how long to treat?

Venous thromboembolism: how long to treat?
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.

Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient

Unprovoked DVT in a young patient
Chapter Nine Venous Disease Coalition New Therapies for VTE VTE Toolkit.

Chapter Nine Venous Disease Coalition New Therapies for VTE VTE Toolkit.
Chapter Three Venous Disease Coalition Epidemiology of VTE Risks, Risk Factors VTE Toolkit.

Chapter Three Venous Disease Coalition Epidemiology of VTE Risks, Risk Factors VTE Toolkit.
Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.

Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.

Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.

Similar presentations

Ads by Google